Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own2.30% Shs Outstand343.78M Perf Week-0.17%
Market Cap7.85B Forward P/E2.89 EPS next Y7.90 Insider Trans2.67% Shs Float332.75M Perf Month5.45%
Income-739.10M PEG- EPS next Q1.56 Inst Own66.80% Short Float9.09% Perf Quarter-36.58%
Sales10.63B P/S0.74 EPS this Y-133.00% Inst Trans20.49% Short Ratio0.98 Perf Half Y-74.24%
Book/sh16.40 P/B1.39 EPS next Y19.18% ROA-1.50% Target Price42.89 Perf Year-91.01%
Cash/sh3.81 P/C5.99 EPS next 5Y7.70% ROE-12.10% 52W Range18.55 - 263.81 Perf YTD-77.55%
Dividend- P/FCF3.90 EPS past 5Y4.40% ROI3.70% 52W High-91.35% Beta0.29
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin75.20% 52W Low23.02% ATR1.38
Employees22000 Current Ratio1.40 Sales Q/Q9.30% Oper. Margin9.90% RSI (14)48.73 Volatility5.15% 6.43%
OptionableYes Debt/Eq5.65 EPS Q/Q-480.80% Profit Margin-7.00% Rel Volume0.76 Prev Close24.48
ShortableYes LT Debt/Eq5.54 EarningsAug 02 BMO Payout- Avg Volume30.97M Price22.82
Recom3.00 SMA203.32% SMA50-6.23% SMA200-65.74% Volume23,444,814 Change-6.78%
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Mar-16-16Reiterated Canaccord Genuity Hold $75 → $40
Mar-16-16Downgrade Nomura Buy → Neutral $175 → $60
Mar-16-16Downgrade CIBC Sector Perform → Sector Underperform
Mar-15-16Downgrade Piper Jaffray Neutral → Underweight
Mar-08-16Reiterated Mizuho Neutral $112 → $70
Mar-02-16Downgrade Canaccord Genuity Buy → Hold $125 → $75
Mar-01-16Downgrade RBC Capital Mkts Outperform → Sector Perform $194 → $85
Feb-29-16Downgrade TD Securities Buy → Hold
Jul-23-16 12:18AM  [$$] Valeant: Not All Delays Are Created Equal at The Wall Street Journal
Jul-22-16 08:29PM  [$$] Overheard at The Wall Street Journal -6.78%
04:40PM  CANADA STOCKS-TSX at highest close in year, 4th weekly gain; telecoms shine
02:16PM  Deficiencies at Bausch + Lomb manufacturing plant in Tampa put glaucoma drug on hold at
12:15PM  Valeant Hits Another Bump
12:11PM  Valeant Slides as FDA Report Hampers Drug Application at TheStreet
11:48AM  Valeant just got blindsided
11:35AM  Valeants latest woe isnt even financial at MarketWatch
11:28AM  Valeant Pharmaceuticals: It Had to End Some Time at
10:34AM  Valeant: Not All Delays Are Created Equal at The Wall Street Journal
10:02AM  Valeant (VRX) Stock Down on Concerns About Glaucoma Treatment
08:44AM  Morning Movers: General Electric Falls on Earnings; Valeant Drops at
07:58AM  Valeant Drug Approval Hampered by FDA Facility Inspection
03:36AM  U.S. FDA raises concerns over Valeant's eye drop Reuters
02:00AM  Valeant Pharmaceuticals Receives Complete Response Letter From The FDA PR Newswire
02:00AM  Valeant Pharmaceuticals Receives Complete Response Letter From The FDA CNW Group
Jul-21-16 04:42PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
03:53PM  BBP: An Outperforming Biotechnology ETF
10:39AM  Valeant & Endo: Imagining a World With No Drug Pricing Controversies at
08:09AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bullish Manner : VRX-US : July 21, 2016
Jul-20-16 04:12PM  Why Progenics Pharmaceuticals, Inc. Shares Soared Today at Motley Fool
03:59PM  Valeant Scores a Rare Win: Have They Turned a Corner?
03:50PM  Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today at Insider Monkey
03:25PM  A tiny clarification on the most positive thing Bill Ackman said during his conference call
03:06PM  These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?
01:51PM  Ackman Defends Valeants Drug Development on Investor Call at Bloomberg
01:50PM  Valeant gets new approval for legacy Salix drug at
01:44PM  Here's Why Jim Cramer Is Positive About Valeant Pharmaceuticals at TheStreet
12:38PM  Pershing Square: An Update on Herbalife and Second Quarter Results at The Wall Street Journal
12:30PM  Valeant's Drug Approvals May Save the Day
12:29PM  Wait, Did Valeant Do Something Right? at Bloomberg
11:47AM  Valeant: Can New Drug Launches Drive Growth?
11:43AM  Can Valeant Pharmaceuticals Intl Inc (VRX) Hit Three For Three Tomorrow? at Insider Monkey
10:41AM  Stocks Move Higher as Crude Oil Pares Losses
10:22AM  Valeant Pharmaceuticals: Two for Two at
10:19AM  Jim Cramer -- Valeant Needs These New Drug Approvals
10:07AM  Valeant (VRX) Stock Gains as FDA Approves Anticonstipation Drug
10:05AM  Could This Be the Turning Point for Progenics and Valeant? at 24/7 Wall St.
09:40AM  Stocks Open Higher; Intuitive Surgical, Microsoft Kick Up
09:36AM  Stocks to Watch: Microsoft, Progenics, Valeant, Morgan Stanley, Zafgen, Halliburton at The Wall Street Journal
09:34AM  Valeant/Progenics Relistor Ok'd; FDA Panel Backs Brodalumab
09:23AM  Here's the Most Overrated Investing Metric You'll Ever See at Motley Fool
09:21AM  Valeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles
09:10AM  Could Fiat Chrysler Become the Valeant of the Auto Industry? at 24/7 Wall St.
08:26AM  Morning Movers: Morgan Stanley Jumps on Earnings; Valeant Pharmaceuticals Climbs on Drug Approval at
08:13AM  Morning Movers: MS, VRX, MSFT, ISRG
Jul-19-16 11:04PM  Futures Point Downward for U.S. Markets as Asia Opens Lower
08:32PM  Valeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics at The Wall Street Journal
06:50PM  Investors Pull $600M After Ackmans Bad Bets at Fortune
06:25PM  Valeant, Progenics shares rise on constipation drug approval at MarketWatch
06:04PM  Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain PR Newswire
06:04PM  Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain CNW Group
05:27PM  [$$] Valeant Gets FDA Panel Recommendation for Psoriasis Drug at The Wall Street Journal
04:53PM  Valeant gets FDA panel recommendation for psoriasis drug at MarketWatch
04:27PM  FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis PR Newswire
04:27PM  FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis CNW Group
04:22PM  U.S. FDA panel backs Valeant psoriasis drug with risk program Reuters
04:21PM  New Valeant (VRX) Drug Gains Approval From FDA Panel
03:45PM  Valeant Drug Should Be Approved With Risk Plan, FDA Advisers Say at Bloomberg
03:40PM  Valeant (VRX) Stock Higher, FDA Panel Backs Psoriasis Drug
03:25PM  U.S. FDA panel backs Valeant psoriasis drug with risk management Reuters
02:24PM  Whats Next for Valeant after Its Former CEO Sold His Holdings?
02:24PM  Inside Bill Ackmans Current Stance and View of His Holdings
01:21PM  ETFs with exposure to Valeant Pharmaceuticals International, Inc. : July 19, 2016
09:37AM  Bill Ackman's Assault on Herbalife Fizzles at Investopedia
Jul-18-16 06:49PM  Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
04:53PM  Valeant Stock Surges Ahead of Anticipated Drug Approval at TheStreet
04:30PM  Valeant Partnership With Walgreens in Trouble: Andrew Left
02:30PM  Valeant-Walgreens Partnership Destined to Flop, Andrew Left Says
01:15PM  Learn from Bill Ackman's Mistakes
12:58PM  Outperform With A Crowded Positions Strategy
12:27PM  Valeant (VRX) Stock Higher Ahead of Anticipated FDA Approval
01:00AM  Pharming Announces Positive Results from Randomized Controlled Trial with RUCONEST® for HAE Prophylaxis PR Newswire
Jul-16-16 01:15PM  Bad year for Wall Street's Golden Boy Ackman AFP
11:41AM  3 Primary Ways Researchers Are Combatting Cancer at Motley Fool
Jul-15-16 09:28PM  U.S. Retail Sales Did Better Than Expected in June; the Nikkei 225 Had a Great Week: Best of Kass
05:41PM  Bill Ackman Just Can't Seem to Catch a Break With Regulators
05:02PM  Bill Ackmans annus horribilis is only getting worse at MarketWatch
04:45PM  Bill Ackman's Herbalife Settles with FTC, Stock Is Undervalued
03:39PM  Valeant Pharmaceuticals' Second-Largest Shareholder Just Abandoned Ship -- Should You, Too? at Motley Fool
01:49PM  Better Buy: Valeant Pharmaceuticals International, Inc. vs. Ionis Pharmaceuticals, Inc. at Motley Fool
12:46PM  Trending Tickers: CBS, VRX, CMG, CTSH
11:29AM  Ackman Again Whipsawed by Herbalife, Valeant as Regulators Disappoint Pershing
11:05AM  Herbalife Spikes On FTC Settlement, Will Fix Rewards Structre
10:52AM  Valeant: Why Long-Term Investors are Pulling Out?
10:25AM  2 Forgotten Activists In Herbalife: David Einhorn And Dan Loeb
09:44AM  Valeant (VRX) Stock Falls on FDA Scrutiny
09:00AM  FDA Staff Split Over Suicide Risk of Valeants Psoriasis Drug at Bloomberg
08:26AM  Valeant psoriasis drug safety challenging to assess -FDA Staff Reuters
08:00AM  Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details PR Newswire
08:00AM  Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details CNW Group
06:58AM  Valeants stock chart warns not to board the bearish bandwagon at MarketWatch
Jul-14-16 06:34PM  Why Cree, Harsco, and Valeant Pharmaceuticals Jumped Today at Motley Fool +6.48%
04:24PM  Valeant (VRX) Stock Closed Higher Today After CEO Statement
03:20PM  Jim Cramer: I'm Watching Valeant and Its Debt Load at TheStreet
01:59PM  Valeant Has Split the Analyst Community
01:10PM  Bill Ackman threw serious shade at the short seller who tanked Valeant
01:00PM  Ackman says Valeant has no current plans to sell core assets at CNBC
12:53PM  Turns out nobody ever really wanted Bill Ackman at Valeant
12:01PM  Why Traders Are Talking About These 5 Stocks Today at Insider Monkey
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM